Xintela has published its report for January-June 2025. The company has implemented a protocol amendment for the phase I/IIa study with XSTEM and reduced the number of patients from 12 to 6. Xintela and EQGen Biomedical has signed a collaboration and license agreement for the development of EQSTEM for horses. The exercise of TO3 warrants provided the company with approximately SEK 10,1 million. After the period, Peter Ekolind appointed COO & VP Commercial Manufacturing.
|
Published August 29, 2025
Xintela publishes half-yearly report
Notes
Flerie and Lipum enter into merger plan
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
NEWSLETTER
Today's news roundup
News roundup Tuesday, November 18
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account